The current study shows LS cohorts consistent with published literature; individuals carrying germline MSH6 pathogenic variants have a reduced risk of developing cancer compared to carriers of MLH1 and MSH2 pathogenic variants4,5, 7, 8, 11, 12. This evidence concerns the gene MLH1 and cancer.